Trials / Completed
CompletedNCT04544813
A Study of JNJ-77474462 in Healthy Participants
A Phase 1 Study to Investigate the Pharmacokinetics and Pharmacodynamics of JNJ-77474462 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the pharmacokinetics (PK) of JNJ-77474462 after single subcutaneous (SC) or intravenous (IV) administrations and the effect of formulation concentrations on PK of JNJ-77474462 in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-77474462 | Participants will receive JNJ-77474462 as a liquid formulation in Cohort A, B, C, D, F and G (SC injection) and in Cohort E, H and I (IV infusion). |
| DRUG | Anakinra | Participants will receive a SC injection of anakinra 100 mg once daily for 3 days. |
Timeline
- Start date
- 2020-10-13
- Primary completion
- 2021-05-30
- Completion
- 2021-05-30
- First posted
- 2020-09-10
- Last updated
- 2023-06-29
Locations
1 site across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04544813. Inclusion in this directory is not an endorsement.